Model of Monoiodoacetate-Induced Osteoarthritis in Laboratory Animals
https://doi.org/10.33647/2713-0428-20-3E-176-181
Abstract
The development of an adequate biomodel of a pathological condition, comparable to the observed clinical case, remains an urgent problem. In order to study the analgesic and anti-inflammatory activity of potential pharmacological substances, it is important to develop inflammation models with signs of cartilage tissue degeneration and pain induced by inflammation. This extends the capabilities of modern approaches. In this work, a model of arthritis induced by monoiodoacetate (MIA) (Sigma-Aldrich, USA) was carried out on rats. To that end, 3 mg of MIA in 50 μl of sterile saline solution was administered intra-articularly into the right knee joint. The model was verified using standard therapy with non-steroidal anti-inflammatory drugs (meloxicam, ibuprofen), which were administered daily from day 3 to day 14 after MIA. Inflammation and behavioral changes associated with pain were assessed on days 3, 7, and 14. On days 8 and 15, the rats were euthanized, and biological material (blood and right knee joint) was collected for histological analysis. The concentration of IL-1β in the synovial fluid was measured on days 8 and 15 after MIA administration to the knee joint of the rats. A single administration of ibuprofen had a pronounced analgesic activity, preventing disability and not weakening the grip strength of the paw into which MIA was administered. At the same time, the selective inhibitor of cyclooxygenase meloxicam was only capable of reducing mechanical hypersensitivity in a von Frey test. Therefore, the effects of a single and course administration were highly similar in terms of the level of influence in pain tests. However, regular administration of cyclooxygenase inhibitors reduced joint inflammation more effectively than a single dose. Meloxicam showed a higher efficiency than ibuprofen in reducing joint inflammation. The results are shown after histological analysis of the knee joint injected with MIA. Thus, a model of osteoarthritis induced by MIA in laboratory animals was developed and characterized.
About the Authors
R. A. Dalevich
Pushchino Branch of the Russian Biotechnological University;
Branch of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Russian Federation
Russian Federation
Renata A. Dalevich
142290, Moscow Region, Pushchino, Nauki Ave., 3;
142290, Moscow Region, Pushchino, Nauki Ave., 6
I. A. Dyachenko
Pushchino Branch of the Russian Biotechnological University;
Branch of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences
Russian Federation
Russian Federation
Igor A. Dyachenko, Dr. Sci. (Biol.), Assoc. Prof.
142290, Moscow Region, Pushchino, Nauki Ave., 3;
142290, Moscow Region, Pushchino, Nauki Ave., 6
References
1. Aspden R.M., Scheven B.A., Hutchison J.D. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Lancet. 2001;357(9262):1118–1120. DOI: 10.1016/S0140-6736(00)04264-1
2. Combe R., Bramwell S., Field M.J. The monosodium iodoacetate model of osteoarthritis: A model of chronic nociceptive pain in rats? Neurosci. Lett. 2004;370 (2-3):236–240. DOI: 10.1016/j.neulet.2004.08.023
3. Fernihough J., Gentry C., Malcangio M., Fox A., Rediske J., Pellas T., Kidd B., Bevan S., Winter J. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain. 2004;112(1-2):83–93. DOI: 10.1016/j.pain.2004.08.004
4. Guingamp C., Gegout-Pottie P., Philippe L., Terlain B., Netter P., Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: A dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997;40(9):1670–1679. DOI: 10.1002/art.1780400917
5. Guzman R.E., Evans M.G., Bove S., Morenko B., Kilgore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: An animal model of osteoarthritis. Toxicol. Pathol. 2003;31(6):619–624. DOI: 10.1080/01926230390241800
6. Liu-Bryan R., Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. Nat. Rev. Rheumatol. 2015;11(1):35–44. DOI: 10.1038/nrrheum.2014.162
7. Martel-Pelletier J., Barr A.J., Cicuttini F.M., Conaghan P.G., Cooper C., Goldring M.B., Goldring S.R., Jones G., Teichtahl A.J., Pelletier J.P. Osteoarthritis. Nat. Rev. Dis. Primers. 2016;2:16072. DOI: 10.1038/nrdp.2016.72
8. Neogi D.S., Kumar A., Rijal L., Yadav C.S., Jaiman A., Nag H.L. Role of nonoperative treatment in managing degenerative tears of the medial meniscus posterior root. J. Orthop. Traumatol. 2013;14(3):193-199. DOI: 10.1007/s10195-013-0234-2.
9. Pomonis J.D., Boulet J.M., Gottshall S.L., Phillips S., Sellers R., Bunton T., Walker K. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain. 2005;114(3):339–346. DOI: 10.1016/j.pain.2004.11.008
10. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J. Pharm. Sci. 2008;11(2):81s–110s. DOI: 10.18433/j3t886
11. Vincent A.T., Schiettekatte O., Goarant C., Neela V.K., Bernet E., Thibeaux R., Ismail N., Mohd Khalid M.K.N., Amran F., Masuzawa T., Nakao R., Amara Korba A., Bourhy P., Veyrier F.J., Picardeau M. Revisiting the taxonomy and evolution of pathogenicity of the genus Leptospira through the prism of genomics. PLoS Negl. Trop. Dis. 2019;13(5):e0007270. DOI: 10.1371/journal.pntd.0007270
12. Yocum D., Castro W., Cornett M. Exercise, education, and behavioral modification as alternative therapy for pain and stress in rheumatic disease. Rheum. Dis. Clin. North Am. 2000;26(1):145–159. DOI: 10.1016/s0889-857x(05)70128-9
Review
For citations:
Dalevich R.A., Dyachenko I.A. Model of Monoiodoacetate-Induced Osteoarthritis in Laboratory Animals. Journal Biomed. 2024;20(3E):176-181. (In Russ.) https://doi.org/10.33647/2713-0428-20-3E-176-181
Views:
77
Email this article 
